ProKidney (NASDAQ:PROK) Raised to “Hold” at Wall Street Zen

ProKidney (NASDAQ:PROK) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

ProKidney Price Performance

PROK stock opened at $0.71 on Thursday. The company has a fifty day moving average price of $0.80 and a two-hundred day moving average price of $1.35. The stock has a market cap of $207.99 million, a price-to-earnings ratio of -1.29 and a beta of 1.50. ProKidney has a one year low of $0.46 and a one year high of $4.35.

ProKidney (NASDAQ:PROK) last announced its earnings results on Monday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $0.23 million during the quarter. Research analysts anticipate that ProKidney will post -0.57 EPS for the current fiscal year.

Insider Activity

In other news, insider Control Empresarial De Capital acquired 1,032,218 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The stock was acquired at an average price of $0.61 per share, with a total value of $629,652.98. Following the completion of the transaction, the insider now directly owns 72,592,325 shares of the company’s stock, valued at $44,281,318.25. This trade represents a 1.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders acquired 1,787,716 shares of company stock valued at $1,175,419. 41.49% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in ProKidney by 65.1% during the third quarter. JPMorgan Chase & Co. now owns 46,830 shares of the company’s stock worth $90,000 after acquiring an additional 18,472 shares in the last quarter. Barclays PLC increased its stake in shares of ProKidney by 17.4% in the fourth quarter. Barclays PLC now owns 171,797 shares of the company’s stock valued at $290,000 after buying an additional 25,476 shares during the period. Renaissance Technologies LLC increased its stake in shares of ProKidney by 127.7% in the fourth quarter. Renaissance Technologies LLC now owns 105,200 shares of the company’s stock valued at $178,000 after buying an additional 59,000 shares during the period. Sei Investments Co. acquired a new position in shares of ProKidney in the fourth quarter valued at approximately $69,000. Finally, Wells Fargo & Company MN increased its stake in shares of ProKidney by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 54,098 shares of the company’s stock valued at $91,000 after buying an additional 18,431 shares during the period. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.